Enlivex Therapeutics Ltd (ENLV) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Enlivex Therapeutics Ltd  (NASDAQ: ENLV)


Enlivex Therapeutics Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Enlivex Therapeutics Ltd's ROI in the fourth quarter of 2025?
Enlivex Therapeutics Ltd achieved a return on average invested assets (ROI) of 114.64 % in its fourth quarter of 2025, this is above ENLV's average return on investment of -78.69%.
Enlivex Therapeutics Ltd invested over the 12 months ending in its fourth quarter of 2025 $1,073 million

ROI has improved compared to -1.68% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 32 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 122.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Investment Change TTM 3539.67 % 1200.34 % -47.81 % -46.93 % -49.47 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 2,318 1,935 19 21 24
Return On Investment (TTM) 114.64 % -1.68 % -54.56 % -147.53 % -123.13 %
ENLV's Overall Ranking # 122 # # # #
Seq. Investment Change TTM 114.79 % 2071.08 % -14.61 % -8.6 % -23.26 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 1,230 -8 -13 -40 -36

ENLV Company Profile >> Back to ENLV Roi Comparisons >> See Annual ENLV Return On Investment



Return On Investment ENLV's Ranking
Within: No.
Industry # 14
Sector # 33
Overall # 122

Return On Investment Statistics
High Average Low
85.35 %
-78.69 %
-566.35 %
(Dec 31 2015)   (Dec 31 2016)







Financial Statements
Enlivex Therapeutics Ltd's IV. Quarter Investments $ 2,318 Millions ENLV's Balance sheet
Enlivex Therapeutics Ltd's IV. Quarter Income $ 1,236 Millions Quarterly ENLV's Income Statement
ENLV's Income by Division See ENLV's Income by Division


ENLV Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,318 24 35 62 90
Y / Y Investment Growth 9724.89 % -32.63 % -43.29 % -31.73 % 146.61 %
Net Income in Millions 1,236 -15 -29 -31 -14
Y / Y Net Income Growth - - - - -
Annual Return On Investment 53.31 % -63.65 % -83.02 % -50.31 % -16 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 53.31 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ENLV's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ENLV's Competitors
Subscribers only: Roi for Enlivex Therapeutics Ltd's Suppliers
Subscribers only: Return On Investment for ENLV's Customers

Other Ratios
ENLV's Roa ENLV's Inventory Turnover Ratio ENLV's Growth Rates ENLV's Dividend Statistics
ENLV's Profitability Ratios ENLV's Asset Turnover Ratio ENLV's Dividend Growth
ENLV's Roe ENLV's Valuation Ratios ENLV's Financial Strength Ratios ENLV's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Oncotelic Therapeutics Inc   252.91 %
Atara Biotherapeutics Inc   242.55 %
Traws Pharma inc   234.73 %
Scisparc Ltd  234.01 %
Petros Pharmaceuticals inc   233.39 %
Omada Health Inc   200.69 %
Interpace Biosciences Inc   198.59 %
Rigel Pharmaceuticals Inc  185.38 %
Icecure Medical Ltd  166.12 %
Silexion Therapeutics Corp  142.64 %
Heartflow Inc   142.09 %
Capforce Inc   140.91 %
Check Cap Ltd  120.45 %
Coherus Oncology inc   119.44 %
Kyntra Bio Inc   118.89 %
Lifemd Inc   105.75 %
Biocryst Pharmaceuticals Inc   88.36 %
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %

Date modified: 2026-07-09T17:12:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.